PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...
At the ESMO 2025 annual meeting, Dr. Hansen and colleagues presented the first-in-human data of 212 Pb-ADVC001 in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback